Evidence map›Paper›PMID 19401190›Full record

ReviewBiochemical and biophysical research communications2009

The RB/E2F pathway and regulation of RNA processing.

Joseph Ahlander, Giovanni Bosco

Abstract readReview
In one paragraph

Review in Biochemical and biophysical research communications, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 29 citations in OpenAlex.

  1. Pathological and Molecular Diagnosis of Uveal Melanoma.Diagnostics (Basel, Switzerland) · 2024
    Review
  2. Review
  3. Review
  4. Review
  5. Transcription Factor E2F1 Regulates the Expression of ADRB2.International journal of analytical chemistry · 2023
    Article
  6. P16INK4A-More Than a Senescence Marker.Life (Basel, Switzerland) · 2022
    Review
  7. Hereditary retinoblastoma iPSC model reveals aberrant spliceosome function driving bone malignancies.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. eNeuro
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Joseph AhlanderDepartment of Molecular and Cellular Biology, 1007 East Lowell Street, University of Arizona, Tucson, AZ 85721, USA.
Giovanni Bosco
University of Arizona · US

Funding

Developmental control of replication by Drosophila RBR01GM069462 · NIGMS · UNIVERSITY OF ARIZONA · PI BOSCO, GIOVANNI · 2004 to 2012
$2.5M
NIGMS NIH HHS GM069462NIGMS NIH HHS R01 GM069462
6 · The paper itself

Abstract

The retinoblastoma tumor suppressor protein (RB) is inactivated in a majority of cancers. RB restricts cell proliferation by inhibiting the E2F family of transcription factors. The current model for RB/E2F function describes its role in regulating transcription at gene promoters. Whether the RB or E2F proteins might play a role in gene expression beyond transcription initiation is not well known. This review describes evidence that points to a novel role for the RB/E2F network in the regulation of RNA processing, and we propose a model as a framework for future research. The elucidation of a novel role of RB in RNA processing will have a profound impact on our understanding of the role of this tumor suppressor family in cell and developmental biology.

Indexed as

RNA Processing, Post-TranscriptionalAnimalsE2F Transcription FactorsHumansRetinoblastoma ProteinRNA-Binding ProteinsTranscription, GeneticE2F Transcription FactorsRetinoblastoma ProteinRNA-Binding Proteins

Identifiers

PMID19401190
PMCPMC3926418
OpenAlexW2063677029

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.